Reference health
Impaired Neutralising Antibodies to SARS-CoV-2 Omicron BA.2 Variant and Preserved Cellular Immunogenicity Following Heterologous Prime-Boost Vaccination with an Inactivated Vaccine Followed by ChAdOx1-nCoV-19 in Patients with Systemic Autoimmune Rheumatic Diseases
20/20 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
10 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 20 checked references that resolve
resolves10.1038/s41591-021-01469-5
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
resolves10.1136/annrheumdis-2021-220647
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
resolves10.1136/annrheumdis-2021-220626
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
resolves10.1016/S2213-2600(21)00357-X
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
resolves10.1586/erv.09.14
Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects
resolves10.3390/vaccines10040536
The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine
resolves10.1080/22221751.2021.1902245
Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
resolves10.1136/annrheumdis-2021-220503
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
resolves10.1016/j.jaut.2021.102744
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
resolves10.1016/j.cell.2021.12.046
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
resolves10.1016/j.cell.2021.12.032
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
resolves10.1038/s41591-021-01507-2
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
resolves10.1136/annrheumdis-2021-221097
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
resolves10.1021/acs.jproteome.8b00811
Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus
resolves10.1002/art.41697
A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases
resolves10.1016/S2665-9913(21)00222-8
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
resolves10.1136/annrheumdis-2021-220862
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis
resolves10.1097/MD.0000000000003637
Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?
resolves10.1136/rmdopen-2021-001898
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
The 10 references without a DOI — listed, not checked
no DOI — not checkedImmunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
no DOI — not checkedMethotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
no DOI — not checkedHeterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
no DOI — not checkedref10
no DOI — not checkedref12
no DOI — not checkedHeterologous prime-boost strategies for COVID-19 vaccines
no DOI — not checkedHeterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
no DOI — not checkedInactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
no DOI — not checkedref17
no DOI — not checkedRituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.4133614"><img src="https://citestamp.com/citestamped/10.2139/ssrn.4133614/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.4133614)